{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T09:45:21Z","timestamp":1773567921866,"version":"3.50.1"},"reference-count":34,"publisher":"American Association for Cancer Research (AACR)","issue":"8","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Triple-negative breast cancers, which lack estrogen receptor, progesterone receptor, and HER2\/neu overexpression, account for approximately 15% of breast cancers, but occur more commonly in African Americans. The poor survival outcomes seen with triple-negative breast cancers patients are, in part, due to a lack of therapeutic targets. Epidermal growth factor receptor (EGFR) is overexpressed in 50% of triple-negative breast cancers, but EGFR inhibitors have not been effective in patients with metastatic breast cancers. However, mTOR inhibition has been shown to reverse resistance to EGFR inhibitors. We examined the combination effects of mTOR inhibition with EGFR inhibition in triple-negative breast cancer in vitro and in vivo. The combination of EGFR inhibition by using lapatinib and mTOR inhibition with rapamycin resulted in significantly greater cytotoxicity than the single agents alone and these effects were synergistic in vitro. The combination of rapamycin and lapatinib significantly decreased growth of triple-negative breast cancers in vivo compared with either agent alone. EGFR inhibition abrogated the expression of rapamycin-induced activated Akt in triple-negative breast cancer cells in vitro. The combination of EGFR and mTOR inhibition resulted in increased apoptosis in some, but not all, triple-negative cell lines, and these apoptotic effects correlated with a decrease in activated eukaryotic translation initiation factor (eIF4E). These results suggest that mTOR inhibitors could sensitize a subset of triple-negative breast cancers to EGFR inhibitors. Given the paucity of effective targeted agents in triple-negative breast cancers, these results warrant further evaluation. Mol Cancer Ther; 10(8); 1460\u20139. \u00a92011 AACR.<\/jats:p>","DOI":"10.1158\/1535-7163.mct-10-0925","type":"journal-article","created":{"date-parts":[[2011,6,21]],"date-time":"2011-06-21T04:56:27Z","timestamp":1308632187000},"page":"1460-1469","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":87,"title":["Combinatorial Effects of Lapatinib and Rapamycin in Triple-Negative Breast Cancer Cells"],"prefix":"10.1158","volume":"10","author":[{"given":"Tongrui","family":"Liu","sequence":"first","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Rami","family":"Yacoub","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"LaTonia D.","family":"Taliaferro-Smith","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Shi-Yong","family":"Sun","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Tisheeka R.","family":"Graham","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Ryan","family":"Dolan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Christine","family":"Lobo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Mourad","family":"Tighiouart","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Lily","family":"Yang","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"},{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Amy","family":"Adams","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]},{"given":"Ruth M.","family":"O'Regan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"},{"name":"Authors' Affiliations:\u20081Department of Hematology and Medical Oncology, Winship Cancer Institute, Departments of 2Biostatistics, 3Surgery, and 4Pathology, Emory University; and 5Georgia Cancer Center for Excellence at Grady Memorial Hospital, Atlanta, Georgia"}]}],"member":"1086","published-online":{"date-parts":[[2011,8,8]]},"reference":[{"key":"2022060800022113500_bib1","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","article-title":"Triple negative tumours: a critical review","volume":"52","author":"Reis-Filho","year":"2008","journal-title":"Histopathology"},{"key":"2022060800022113500_bib2","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","article-title":"Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study","volume":"295","author":"Carey","year":"2006","journal-title":"JAMA"},{"key":"2022060800022113500_bib3","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10549-008-9926-3","article-title":"Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA","volume":"113","author":"Lund","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2022060800022113500_bib4","doi-asserted-by":"crossref","first-page":"8418","DOI":"10.1073\/pnas.0932692100","article-title":"Repeated observation of breast tumor subtypes in independent gene expression data sets","volume":"100","author":"Sorlie","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022060800022113500_bib5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0140-6736(97)11423-4","article-title":"Tamoxifen for early breast cancer: An overview of the randomised trials","volume":"351","author":"Clarke","year":"1998","journal-title":"Lancet"},{"key":"2022060800022113500_bib6","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa052122","article-title":"Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer","volume":"353","author":"Romond","year":"2005","journal-title":"N Engl J Med"},{"key":"2022060800022113500_bib7","doi-asserted-by":"crossref","first-page":"5367","DOI":"10.1158\/1078-0432.CCR-04-0220","article-title":"Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma","volume":"10","author":"Nielsen","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2022060800022113500_bib8","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/chemse\/19.1.57","article-title":"Olfactory function in patients with hypogonadotropic hypogonadism: an all-or-none phenomenon?","volume":"19","author":"Hudson","year":"1994","journal-title":"Chem Senses"},{"key":"2022060800022113500_bib9","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-008-0055-9","article-title":"Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer","volume":"115","author":"Dickler","year":"2009","journal-title":"Breast Cancer Res Treat"},{"key":"2022060800022113500_bib10","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1200\/JCO.2005.08.326","article-title":"Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer","volume":"23","author":"Baselga","year":"2005","journal-title":"J Clin Oncol"},{"key":"2022060800022113500_bib11","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1200\/jco.2008.26.15_suppl.1009","article-title":"On behalf of the Translational Breast Cancer Research Consortium TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer","volume":"26","author":"Carey","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060800022113500_bib12","first-page":"p. 407","article-title":"A phase II trial of a mammalian target of rapamycin inhibitor, temsirolimus, in patients with metastatic breast cancer","author":"Hahn","year":"2008","journal-title":"SABCS"},{"key":"2022060800022113500_bib13","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1158\/0008-5472.CAN-05-0917","article-title":"Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition","volume":"65","author":"Sun","year":"2005","journal-title":"Cancer Res"},{"key":"2022060800022113500_bib14","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-05-2925","article-title":"mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt","volume":"66","author":"O'Reilly","year":"2006","journal-title":"Cancer Res"},{"key":"2022060800022113500_bib15","first-page":"p. 3119","article-title":"RAD001 (everolimus) in combination with weekly paclitaxel and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab: a multicenter phase I clinical trial","author":"O'Regan","year":"2008","journal-title":"SABCS"},{"key":"2022060800022113500_bib16","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1158\/1535-7163.MCT-06-0166","article-title":"Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors","volume":"5","author":"Buck","year":"2006","journal-title":"Mol Cancer Ther"},{"key":"2022060800022113500_bib17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1002\/ijc.23585","article-title":"Synergistic inhibition of head and neck tumor growth by green tea (-)-epigallocatechin-3-gallate and EGFR tyrosine kinase inhibitor","volume":"123","author":"Zhang","year":"2008","journal-title":"Int J Cancer"},{"key":"2022060800022113500_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv Enzyme Regul"},{"key":"2022060800022113500_bib19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol Rev"},{"key":"2022060800022113500_bib20","doi-asserted-by":"crossref","first-page":"834","DOI":"10.2307\/2532796","article-title":"Simple designs and model-free tests for synergy","volume":"50","author":"Laska","year":"1994","journal-title":"Biometrics"},{"key":"2022060800022113500_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1259\/dmfr\/55276404","article-title":"Density conversion factor determined using a cone-beam computed tomography unit NewTom QR-DVT 9000","volume":"35","author":"Lagravere","year":"2006","journal-title":"Dentomaxillofac Radiol"},{"key":"2022060800022113500_bib22","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jsat.2006.04.002","article-title":"Behavioral HIV risk reduction among people who inject drugs: meta-analytic evidence of efficacy","volume":"31","author":"Copenhaver","year":"2006","journal-title":"J Subst Abuse Treat"},{"key":"2022060800022113500_bib23","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0955-0674(98)80150-6","article-title":"The mRNA 5\u2032 cap-binding protein eIF4E and control of cell growth","volume":"10","author":"Sonenberg","year":"1998","journal-title":"Curr Opin Cell Biol"},{"key":"2022060800022113500_bib24","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.1101\/gad.1604407","article-title":"Dissecting eIF4E action in tumorigenesis","volume":"21","author":"Wendel","year":"2007","journal-title":"Genes Dev"},{"key":"2022060800022113500_bib25","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.4161\/cbt.7.12.6944","article-title":"Overcoming mTOR inhibition-induced paradoxical activation of survival signaling pathways enhances mTOR inhibitors' anticancer efficacy","volume":"7","author":"Wang","year":"2008","journal-title":"Cancer Biol Ther"},{"key":"2022060800022113500_bib26","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1200\/JCO.2004.08.095","article-title":"Breast cancer with synchronous metastases: trends in survival during a 14-year period","volume":"22","author":"Andre","year":"2004","journal-title":"J Clin Oncol"},{"key":"2022060800022113500_bib27","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1200\/jco.2008.26.15_suppl.1018","article-title":"Prognosis of women with stage IV breast cancer by HER2 status and trastuzumab treatment: an institutional based review","volume":"26","author":"Dawood","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060800022113500_bib28","article-title":"Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER\/PR\/HER2-negative breast cancer resistant to anthracyclines and taxanes","author":"Rugo","year":"2007","journal-title":"SABCS"},{"key":"2022060800022113500_bib29","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N Engl J Med"},{"key":"2022060800022113500_bib30","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/14622200600789551","article-title":"Couple dynamics during women's tobacco reduction in pregnancy and postpartum","volume":"8","author":"Bottorff","year":"2006","journal-title":"Nicotine Tob Res"},{"key":"2022060800022113500_bib31","first-page":"p. 308","article-title":"Preliminary results of a randomized phase II study of weekly irinotecan\/carboplatin with or without cetuximab in patients with metastatic breast cancer","author":"O'Shaughnessy","year":"2007","journal-title":"SABCS"},{"key":"2022060800022113500_bib32","doi-asserted-by":"crossref","first-page":"7409","DOI":"10.1158\/0008-5472.CAN-08-1522","article-title":"Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR\/raptor inhibition-initiated, mTOR\/rictor-independent Akt activation","volume":"68","author":"Wang","year":"2008","journal-title":"Cancer Res"},{"key":"2022060800022113500_bib33","doi-asserted-by":"crossref","first-page":"5544","DOI":"10.1200\/JCO.2008.16.2578","article-title":"Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer","volume":"26","author":"Di Leo","year":"2008","journal-title":"J Clin Oncol"},{"key":"2022060800022113500_bib34","doi-asserted-by":"crossref","first-page":"8051","DOI":"10.1200\/jco.2008.26.15_suppl.8051","article-title":"A phase 1\/2 study investigating the combination of RAD001 (R) (everolimus) and erlotinib (E) as 2nd and 3rd line therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy (C): phase 1 results","volume":"26","author":"Papadimitrakopoulou","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Molecular Cancer Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/10\/8\/1460\/2320118\/1460.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/mct\/article-pdf\/10\/8\/1460\/2320118\/1460.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:08:36Z","timestamp":1654646916000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/mct\/article\/10\/8\/1460\/91120\/Combinatorial-Effects-of-Lapatinib-and-Rapamycin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,1]]},"references-count":34,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2011,8,8]]},"published-print":{"date-parts":[[2011,8,1]]}},"URL":"https:\/\/doi.org\/10.1158\/1535-7163.mct-10-0925","relation":{},"ISSN":["1535-7163","1538-8514"],"issn-type":[{"value":"1535-7163","type":"print"},{"value":"1538-8514","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,1]]}}}